LEVOTHYROXINE SODIUM - Generic Drug Details

What are the generic sources for levothyroxine sodium and what is the scope of patent protection?

Levothyroxine sodium is the generic ingredient in twelve branded drugs marketed by Ani Pharms, Ibsa, Dr Reddys, Fresenius Kabi Usa, Maia Pharms Inc, Onesource Specialty, Ph Health, Piramal Critical, Xiromed, Zydus Pharms, Hikma, Mylan, Stevens J, Emd Serono Inc, Cediprof Inc, Genus Lifesciences, Accord Hlthcare, Amneal, Ascent Pharms Inc, Aurobindo Pharma, Lupin, Macleods Pharms Ltd, Merck Kgaa, Watson Labs Teva, King Pharms, Abbvie, and Alvogen, and is included in thirty-two NDAs. There are fifteen patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Levothyroxine sodium has fifty-one patent family members in seventeen countries.

There are ten drug master file entries for levothyroxine sodium. Fifty-four suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for LEVOTHYROXINE SODIUM

International Patents:	51
US Patents:	15
Tradenames:	12
Applicants:	27
NDAs:	32
Drug Master File Entries:	10
Finished Product Suppliers / Packagers:	54
Raw Ingredient (Bulk) Api Vendors:	73
Clinical Trials:	27
Patent Applications:	3,928
Drug Sales Revenues:	Drug sales revenues for LEVOTHYROXINE SODIUM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LEVOTHYROXINE SODIUM
What excipients (inactive ingredients) are in LEVOTHYROXINE SODIUM?	LEVOTHYROXINE SODIUM excipients list
DailyMed Link:	LEVOTHYROXINE SODIUM at DailyMed

See drug sales revenues for LEVOTHYROXINE SODIUM

Recent Clinical Trials for LEVOTHYROXINE SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Peking University	EARLY_PHASE1
University of Pennsylvania	Phase 4
National Institute on Aging (NIA)	Phase 4

See all LEVOTHYROXINE SODIUM clinical trials

Generic filers with tentative approvals for LEVOTHYROXINE SODIUM

Applicant	Application No.	Strength	Dosage Form
		200MCG/VIAL	POWDER;INTRAVENOUS

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for LEVOTHYROXINE SODIUM

Drug Class

l-Thyroxine

Anatomical Therapeutic Chemical (ATC) Classes for LEVOTHYROXINE SODIUM

H03AA	Thyroid hormones
H03A	THYROID PREPARATIONS
H03	THYROID THERAPY
H	Systemic hormonal preparations, excluding sex hormones and insulins

Paragraph IV (Patent) Challenges for LEVOTHYROXINE SODIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
THYQUIDITY	Oral Solution	levothyroxine sodium	100 mcg/5 mL	214047	1	2022-12-28
TIROSINT	Capsules	levothyroxine sodium	137 mcg and 175 mcg	021924	1	2022-11-04
TIROSINT-SOL	Oral Solution	levothyroxine sodium	13 mcg/mL 25 mcg/mL 50 mcg/mL 75 mcg/mL 88 mcg/mL 100 mcg/mL 112 mcg/mL 125 mcg/mL 137 mcg/mL 150 mcg/mL 175 mcg/mL 200 mcg/mL	206977	1	2022-09-30
TIROSINT	Capsules	levothyroxine sodium	200 mcg	021924	1	2021-12-30
TIROSINT	Capsules	levothyroxine sodium	112 mcg	021924	1	2020-12-18
TIROSINT	Capsules	levothyroxine sodium	88 mcg, 100 mcg and 125 mcg	021924	1	2019-08-01
TIROSINT	Capsules	levothyroxine sodium	75 mcg and 150 mcg	021924	1	2017-12-29
LEVOTHYROXINE SODIUM	for Injection	levothyroxine sodium	200 mcg/vial	202231	1	2015-05-01
LEVOTHYROXINE SODIUM	for Injection	levothyroxine sodium	100 mcg/vial and 500 mcg/vial	202231	2	2015-04-14

US Patents and Regulatory Information for LEVOTHYROXINE SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xiromed	LEVOTHYROXINE SODIUM	levothyroxine sodium	POWDER;INTRAVENOUS	217495-001	Nov 29, 2024	AP	RX	No	No
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-006	Mar 1, 2002	AB1,AB2,AB3	RX	No	No
Ascent Pharms Inc	LEVOTHYROXINE SODIUM	levothyroxine sodium	TABLET;ORAL	215259-007	Jan 18, 2023	AB4	RX	No	No
Genus Lifesciences	LEVOLET	levothyroxine sodium	TABLET;ORAL	021137-009	Jun 6, 2003	AB1,AB2,AB3,AB4	RX	No	No	10,406,108		Y
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-002	Dec 15, 2016		RX	Yes	No	11,241,382

Expired US Patents for LEVOTHYROXINE SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-001	Mar 1, 2002	6,399,101
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-008	May 25, 2001	7,101,569
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-007	May 25, 2001	7,067,148
King Pharms	LEVOXYL	levothyroxine sodium	TABLET;ORAL	021301-001	May 25, 2001	6,555,581
Ibsa	TIROSINT	levothyroxine sodium	CAPSULE;ORAL	021924-004	Oct 13, 2006	7,691,411

International Patents for LEVOTHYROXINE SODIUM

Country	Patent Number	Title	Estimated Expiration
Hungary	E052092
Croatia	P20151421
European Patent Office	2683361	MÉTHODE DE MANUFACTURE D'UNE SOLUTION DE LÉVOTHYROXINE (METHOD FOR THE PREPARATON OF A LEVOTHYROXINE SOLUTION)
World Intellectual Property Organization (WIPO)	2018102145
China	113645966

Levothyroxine Sodium: Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

How big is the levothyroxine sodium market, and what drives demand?

Levothyroxine sodium is the reference standard for hypothyroidism and a core therapy in endocrinology. Demand is driven by (1) prevalence of hypothyroidism, (2) long-duration, often lifelong dosing, and (3) ongoing incident cases from aging populations and treatment for thyroid dysfunction.

Key demand characteristics

• Chronic use profile: Most patients remain on therapy for years or life, which makes the market structurally “sticky.”
• Clinical substitution patterns: Switching between products can occur based on payer formularies, generic entry, and pharmacy availability.
• Formulation and delivery effects: Oral levothyroxine remains dominant, with competitive pressure coming from generic and authorized generic supply as patents expire.

Market maturity and pricing structure Levothyroxine sodium is a mature, widely genericized market. Pricing is shaped by:

• Generic-led price compression after multiple entrants and large-scale manufacturing.
• Channel mix: Greater share of volume via mass retail and PBM-driven formulary placement.
• Manufacturing resilience: Supply continuity is a material variable because demand is steady and dosing is time-sensitive.

What are the main competitive dynamics shaping growth?

The market dynamics are dominated by the generic ecosystem and brand positioning where brands retain share via clinician/patient preference, switching reluctance, or payer policies.

Competitive forces that move share

• Patent and exclusivity timing across legacy brands
• Generic market entry waves tied to ANDA approvals and launch readiness
• Interchangeability and switching policy within health systems and payer formularies
• Supply availability and bottleneck risk (levothyroxine shortages have historically emerged in multiple jurisdictions)

Positioning reality

• Brands tend to defend share through managed access and continuity narratives.
• Generics compete on price, which compresses net revenue unless a producer has strong channel access, large-scale manufacturing, or a defensible product lifecycle (e.g., authorized generics, distinct dosage forms, or line expansions).

How does substitution risk affect financial trajectory?

Levothyroxine has narrow clinical thresholds, so product changes can create monitoring and adherence costs. While clinical guidance generally supports switching with monitoring, real-world payer and provider behavior still affects uptake.

Mechanisms that influence revenue

• Switch friction: Providers may prefer continuity in stable patients, slowing generic capture in segments where brand continuity is enforced.
• Monitoring costs: When switches occur, labs and physician visits rise, affecting payer economics even if drug unit prices fall.
• Adherence sensitivity: Small changes in availability or formulation can increase discontinuation risk, which can reduce net sales volume.

Net effect on financials

• Unit price trend: Downward over time as generic competition increases.
• Net revenue stability: Often partially buffered by chronic use, but margin pressure intensifies with each new entrant.

What does the financial trajectory look like under generic pressure?

For levothyroxine sodium, the financial trajectory typically follows a mature “value erosion” pattern: strong historical brand revenue decays as generics expand, then plateaus at a lower price level due to stable demand.

Trajectory pattern by phase

1. Pre-maturity / brand dominance
   • Higher gross margins and premium pricing.
2. Early generic entry
   • Rapid share loss and sharp net price decline.
3. Late generic consolidation
   • Price stabilization at a low-to-moderate level, with margins governed by manufacturing scale and supply reliability.
4. Ongoing competition
   • Incremental market share shifts occur via stocking, reimbursement, and supply execution rather than product innovation.

Which regulatory and supply factors matter most for revenue and margins?

Levothyroxine sodium is sensitive to manufacturing and quality systems because dosing precision and consistent bioavailability matter. Revenue volatility can occur if supply disruptions happen.

Revenue-impacting factors

• Quality and GMP compliance: recalls or manufacturing slowdowns can temporarily reduce sellable supply and shift demand to competitors.
• Regulatory actions: label changes, abbreviated approval structures, and interchangeability policies can influence formulary outcomes.
• Supply disruptions: shortages raise demand for available inventory, shifting near-term revenue to the most reliable producers.
• Product lifecycle management: dosage-form expansions and line extensions can protect revenue for specific manufacturers.

What are the typical revenue levers for manufacturers in this market?

In mature levothyroxine sodium, financial outcomes are largely a function of execution rather than innovation.

Primary revenue levers

• Volume growth through formulary wins and channel penetration
• Net price management via mix (strengths, package sizes, and payer segment allocation)
• Manufacturing cost leadership
  • scale utilization,
  • yield and batch efficiency,
  • logistics optimization.
• Supply reliability
  • maintaining uninterrupted shipments to wholesalers and major retail chains.

How do pricing and reimbursement trends change over time?

As generic penetration increases, reimbursement typically aligns with:

• Lower wholesale acquisition costs and steep declines in price per tablet for the dominant generics.
• Higher share of low-cost SKUs, especially once payers standardize to a small number of preferred products.
• Reduced brand price premiums unless a brand retains a unique formulary position.

Financial implication

• Even if total units remain stable or grow with population and incidence, revenue growth often lags behind volume due to sustained net price erosion.

What do recent data sources indicate about market positioning and baseline demand?

Publicly available market analytics generally treat levothyroxine sodium as a large, stable endocrine therapy class with growth tied to demographic drivers and treatment continuity. Industry coverage consistently places the product in mature, highly generic markets where revenue depends on unit economics and supply execution rather than patent-protected novelty.

Evidence base in this analysis

• Levothyroxine is a standard-of-care for hypothyroidism. FDA labeling and clinical pharmacology guidance underpin its long-term use profile. (FDA product information and prescribing references support chronic hypothyroidism dosing and clinical monitoring.) [1]
• Market and industry reporting frameworks classify levothyroxine as a mature, generic-dominant category. (Trade and market research sources characterize the market’s generic structure and competitive pricing pressure.) [2]

What does the investment view imply for near-term financial performance?

For investors, the near-term story is less about innovation and more about:

• unit-cost performance (manufacturing economics),
• market share via contracting and supply reliability, and
• margin protection through portfolio scale.

Key financial risks

• Margin compression as additional generic entrants drive net price down.
• Supply constraints that either reduce volume (if a producer is impaired) or transfer volume to competitors (if a producer is unaffected).
• Policy-driven switching changes by payers and systems, which can shift share between preferred products.

How does product-level strategy translate into financial outcomes?

Manufacturers typically respond through:

• strength and dosage SKU rationalization to maximize throughput on the most demanded formulations,
• authorized generic strategies where available, and
• portfolio bundling (leveraging shared manufacturing lines and distribution relationships across endocrine products).

Outcome

• Producers with scale and reliable supply tend to protect unit volume and maintain better margins in a low-price environment.
• Smaller entrants often experience sharper margin volatility due to higher manufacturing and distribution costs and weaker contracting power.

---

Key Takeaways

• Levothyroxine sodium is a mature, chronically dosed endocrine therapy, so demand is stable while net pricing erodes under generic competition.
• Financial trajectory follows a predictable pattern: brand revenue decay, rapid generic-driven net price decline, then low-margin stabilization with revenue governed by unit economics and supply execution.
• Revenue and profit are primarily driven by formulary placement, contracting, manufacturing scale, and uninterrupted supply rather than product innovation.
• Near-term financial performance depends on cost leadership and distribution reliability, with upside and downside stemming from market-share shifts during supply constraints and payer-driven switching behavior.

---

FAQs

1) Is levothyroxine sodium expected to grow faster in volume or revenue?

Volume tends to be steadier due to chronic use and demographic drivers. Revenue growth usually lags because net prices decline as generic competition expands.

2) What most commonly determines market share in levothyroxine sodium?

Formulary status, PBM contracting, retail stocking patterns, and the ability to supply uninterrupted inventory at low cost.

3) Why can switching between levothyroxine products affect payers financially?

Switches can trigger increased monitoring and physician follow-ups due to dosing sensitivity, changing total cost of care even when drug unit prices fall.

4) What operational factors can create short-term revenue swings?

Manufacturing outages, quality events, distribution bottlenecks, and shortage conditions that redirect demand to the most available suppliers.

5) What business strategies tend to protect margins in this category?

Scale manufacturing, cost-per-tablet optimization, strong contracting, and dosage-form portfolio management that prioritizes high-turn SKUs.

---

References (APA)

[1] U.S. Food and Drug Administration. (n.d.). Levothyroxine sodium prescribing information / drug label information (product-specific labeling through FDA resources). https://www.fda.gov/
[2] IQVIA / industry market research coverage (public summaries). (n.d.). Levothyroxine sodium market structure and generic competition overview. https://www.iqvia.com/